* This is a professional Version *
Erectile dysfunction is the inability to attain or sustain an erection satisfactory for sexual intercourse. Most erectile dysfunction is related to vascular, neurologic, psychologic, and hormonal disorders; drug use can also be a cause. Evaluation typically includes screening for underlying disorders and measuring testosterone levels. Treatment options include oral phosphodiesterase inhibitors, intraurethral or intracavernosal prostaglandins, vacuum erection devices, and surgical implants.
Erectile dysfunction (ED; formerly called impotence) affects up to 20 million men in the US. The prevalence of partial or complete ED is > 50% in men aged 40 to 70, and prevalence increases with aging. Most affected men can be successfully treated.
There are 2 types of ED:
Primary ED is rare and is almost always due to psychologic factors or clinically obvious anatomic abnormalities.
Secondary ED is more common, and > 90% of cases have an organic etiology. Many men with secondary ED develop reactive psychologic difficulties that compound the problem.
Psychologic factors, whether primary or reactive, must be considered in every case of ED. Psychologic causes of primary ED include guilt, fear of intimacy, depression, or anxiety. In secondary ED, causes may relate to performance anxiety, stress, or depression. Psychogenic ED may be situational, involving a particular place, time, or partner.
The major organic causes of ED are
These disorders often stem from atherosclerosis or diabetes.
The most common vascular cause is atherosclerosis of cavernous arteries of the penis, often caused by smoking and diabetes. Atherosclerosis and aging decrease the capacity for dilation of arterial blood vessels and smooth muscle relaxation, limiting the amount of blood that can enter the penis (see Overview of Male Sexual Function : Erection). Veno-occlusive dysfunction permits venous leakage, which results in inability to maintain erection.
Priapism, usually associated with trazodone use, cocaine abuse, and sickle cell disease, may cause penile fibrosis and lead to ED by causing fibrosis of penile veins that interferes with drainage.
Neurologic causes include stroke, partial complex seizures, multiple sclerosis, peripheral and autonomic neuropathies, and spinal cord injuries. Diabetic neuropathy and surgical injury are particularly common causes.
Complications of pelvic surgery (eg, radical prostatectomy [even with nerve-sparing techniques], radical cystectomy, transurethral resection of the prostate, rectal cancer surgery) are other common causes. Other causes include hormonal disorders, drugs, pelvic radiation, and structural disorders of the penis (eg, Peyronie disease). Prolonged perineal pressure (as occurs during bicycle riding) or pelvic or perineal trauma can cause ED.
Any endocrinopathy or aging associated with testosterone deficiency ( hypogonadism) may decrease libido and cause ED. However, erectile function only rarely improves with normalization of serum testosterone levels because most affected men also have neurovascular causes of ED.
Numerous drug causes are possible (see Table: Commonly Used Drugs That Can Cause Erectile Dysfunction). Alcohol can cause temporary ED.
Evaluation should include history of drug (including prescription drugs and herbal products) and alcohol use, pelvic surgery and trauma, smoking, diabetes, hypertension, and atherosclerosis and symptoms of vascular, hormonal, neurologic, and psychologic disorders. Satisfaction with sexual relationships should be explored, including evaluation of partner interaction and partner sexual dysfunction (eg, atrophic vaginitis, dyspareunia, depression).
It is vital to screen for depression, which may not always be apparent. The Beck Depression Scale or, in older men, the Yesavage Geriatric Depression Scale (see Table: Geriatric Depression Scale (Short Form)) is easy to administer and may be useful.
Examination is focused on the genitals and extragenital signs of hormonal, neurologic, and vascular disorders. Genitals are examined for anomalies, signs of hypogonadism, and fibrous bands or plaques (Peyronie disease). Poor rectal tone, decreased perineal sensation, or abnormal bulbocavernosus reflexes may indicate neurologic dysfunction. Diminished peripheral pulses suggest vascular dysfunction.
A psychologic cause should be suspected in young healthy men with abrupt onset of ED, particularly if onset is associated with a specific emotional event or if the dysfunction occurs only in certain settings. A history of ED with spontaneous improvement also suggests psychologic origin (psychogenic ED). Men with psychogenic ED usually have normal nocturnal erections and erections upon awakening, whereas men with organic ED often do not.
Commonly Used Drugs That Can Cause Erectile Dysfunction
Laboratory assessment should include measurement of morning testosterone level; if the level is low or low-normal, prolactin and luteinizing hormone (LH) should be measured. Evaluation for occult diabetes, dyslipidemias, hyperprolactinemia, thyroid disease, and Cushing syndrome should be done based on clinical suspicion.
Currently, duplex ultrasonography after intracavernous injection of a vasoactive drug such as prostaglandin E 1 is most often used to evaluate penile vasculature. Normal values include a peak systolic flow velocity > 20 cm/sec and a resistive index > 0.8. Resistive index is the difference between peak systolic velocity and end-diastolic velocity divided by peak systolic velocity. Rarely, in selected patients for whom penile revascularization surgery is being considered after pelvic trauma, dynamic infusion cavernosography and cavernosometry may be done.
Underlying organic disorders (eg, diabetes, hypogonadism, Peyronie disease) require appropriate treatment. Drugs that are temporally related to onset of ED should be stopped or switched. Depression may require treatment. For all patients, reassurance and education (including of the patient’s partner whenever possible) are important.
For further therapy, an oral phosphodiesterase inhibitor is tried first. If necessary, another noninvasive method, such as a vacuum erection device or intracavernosal or intraurethral prostaglandin E 1 is tried next. Invasive treatments are used only when noninvasive methods fail. All drugs and devices should be tried ≥ 5 times before being considered ineffective.
First-line treatment of ED is usually an oral phosphodiesterase inhibitor. Other drugs used include intracavernosal or intraurethral prostaglandin E 1 . However, because almost all patients prefer oral drug therapy, oral drugs are used unless they are contraindicated or not tolerated.
Oral phosphodiesterase inhibitors selectively inhibit cyclic guanosine monophosphate (cGMP)–specific phosphodiesterase type 5 (PDE5), the predominant phosphodiesterase isoform in the penis. These drugs include sildenafil, vardenafil, avanafil, and tadalafil (see Table: Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction). By preventing the hydrolysis of cGMP, these drugs promote the cGMP-dependent smooth muscle relaxation that is essential for normal erection. Although vardenafil and tadalafil are more selective for the penile vasculature than sildenafil, clinical responses and adverse effects of these drugs are similar. In comparative clinical trials, these drugs show comparable efficacy (60 to 75%).
Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction
All PDE5 inhibitors cause direct coronary vasodilation and potentiate the hypotensive effects of other nitrates, including those used to treat coronary artery disease as well as recreational amyl nitrate (“poppers”). Thus, the concomitant use of nitrates and PED5 inhibitors can be dangerous and should be avoided. Patients who only occasionally use nitrates (eg, for rare bouts of angina) should discuss the risks, selection, and proper timing of possible PDE5 inhibitor use with a cardiologist.
Adverse effects of PDE5 inhibitors include flushing, visual abnormalities, hearing loss, dyspepsia and headache. Sildenafil and vardenafil may cause abnormal color perception (blue haze). Tadalafil use has been linked with myalgias. Rarely, nonarteritic ischemic optic neuropathy (NAION ) has been associated with PDE5 inhibitor use, but a causal relationship has not been established. All PDE5 inhibitors should be administered cautiously and at lower initial dosages to patients receiving α-blockers (eg, prazosin, terazosin, doxazosin, tamsulosin) because of the risk of hypotension. Patients taking an α-blocker should wait at least 4 h before using a PDE5 inhibitor. Rarely, PDE5 inhibitors cause priapism.
Alprostadil (prostaglandin E 1 ), self-administered via intraurethral insertion or intracavernosal injection, can produce erections with a mean duration of 30 to 60 min. Intracavernous alprostadil may be compounded with papaverine and phentolamine for increased efficacy when necessary. Excessive dosing may cause priapism in ≤ 1% of patients and genital or pelvic pain in about 10%. Office teaching and monitoring by the physician helps achieve optimal and safe use, including minimizing the risk of prolonged erection. Intraurethral therapy is less effective at producing satisfactory erection (up to 60% of men) than intracavernosal injection (up to 90%). Combination therapy with a PDE5 inhibitor and intraurethral alprostadil may be useful for some patients who fail to respond to oral PDE5 inhibitors alone.
Men who can develop but not sustain an erection may use a constriction ring to help maintain erection; an elastic ring is placed around the base of the erect penis, preventing early loss of erection. Men who cannot achieve erection can first use a vacuum erection device that draws blood into the penis via suction, after which an elastic ring is placed at the base of the penis to maintain the erection. Bruising of the penis, coldness of the tip of the penis, and lack of spontaneity are some drawbacks to this modality. These devices can also be combined with drug therapy if needed.
If drugs and vacuum devices fail, surgical implantation of a penile prosthesis can be considered. Prostheses include semirigid silicone rods and saline-filled multicomponent inflatable devices. Both models carry the risks of general anesthesia, infection, and prosthesis erosion or malfunction. With experienced surgeons, the long-term rate of infection or malfunction is well below 5% and the rate of patient and partner satisfaction is > 95%.
Vascular, neurologic, psychologic, and hormonal disorders and sometimes drug use can compromise achievement of satisfactory erections.
Evaluate all men with ED for hormonal, neurologic, and vascular disorders and depression.
Measure testosterone levels and consider other testing based on clinical findings.
Treat underlying disorders and use an oral PDE5 inhibitor if necessary.
If those measures are ineffective, consider intracavernosal or intraurethral prostaglandin E 1 or use of a vacuum device; surgical implantation of a penile prosthesis is the final line of treatment.
Drug NameSelect Trade
papaverineNo US brand name
AlprostadilCAVERJECT, EDEX, MUSE
* This is a professional Version *